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Surveillance and outbreak reports
Escherichia coli and Staphylococcus aureus: bad news 
and good news from the European Antimicrobial 
Resistance Surveillance Network (EARS-Net, formerly 
EARSS), 2002 to 2009
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Based on data collected by the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) and the 
former EARSS, the present study describes the trends 
in antimicrobial susceptibility patterns and occur-
rence of invasive infections caused by Escherichia coli 
and Staphylococcus aureus in the period from 2002 
to 2009. Antimicrobial susceptibility results from 
198 laboratories in 22 European countries reporting 
continuously on these two microorganisms during 
the entire study period were included in the analy-
sis. The number of bloodstream infections caused by 
E. coli increased remarkably by 71% during the study 
period, while bloodstream infections caused by 
S. aureus increased by 34%. At the same time, an 
alarming increase of antimicrobial resistance in E. coli 
was observed, whereas for S. aureus the proportion of 
meticillin resistant isolates decreased. The observed 
trend suggests an increasing burden of disease caused 
by E. coli. The reduction in the proportion of meticillin-
resistant S. aureus and the lesser increase in S. aureus 
infections, compared with E. coli, may reflect the suc-
cess of infection control measures at hospital level in 
several European countries.
Introduction





The	 antimicrobial	 susceptibility	 of	 these	 microorgan-
isms	 and	 other	 selected	 bacterial	 pathogens	 causing	
invasive	 infections	 has	 been	 monitored	 for	 a	 decade	
by	the	European	Antimicrobial	Resistance	Surveillance	
System	 (EARSS)	 [1].	 Coordination	 and	 administra-
tion	 of	 the	 EARSS	 project,	 previously	 conducted	 by	
the	 Dutch	 National	 Institute	 of	 Public	 Health	 and	 the	





bial	 susceptibility	 data	 referring	 to	 2009)	 took	 place	
during	June	and	July	2010.	
Whereas	 detailed	 analysis	 and	 trends	 at	 the	 national	
level	are	available	in	the	EARSS	and	EARS-Net	reports	
[1,2],	 the	 present	 study	 describes	 the	 trends	 in	 sus-
ceptibility	 patterns	 and	 number	 of	 invasive	 infections	
caused	by	E. coli	and	S. aureus	in	Europe	from	2002	to	
2009,	based	on	data	 from	 laboratories	 reporting	con-
tinuously	during	this	period.	
Methods 
Data	 for	 E. coli	 and	 S. aureus	 BSIs	 were	 extracted	
from	the	EARSS/EARS-Net	database	for	a	convenience	
sample	of	 laboratories	 reporting	susceptibility	 results	
continuously	during	 the	period	 from	2002	 to	2009	 for	
aminopenicillin,	 fluoroquinolones,	 third	 generation	




ism	 per	 year)	 were	 not	 included	 in	 the	 analysis.	 Only	
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the	 first	 isolate	 per	 patient,	 microorganism	 and	 year	
was	 included	 as	 a	 representative	 sample.	 Sampling	
and	processing	of	isolates	was	done	in	agreement	with	
the	 EARSS	 manual	 2005	 [3].	 Resistance	 (R	 category	
of	S,	 I,	R)	was	defined	by	 the	guidelines	 in	use	 in	 the	
reporting	countries.	
The	 number	 of	 BSIs	 caused	 by	 E. coli	 and	 S. aureus	
and	the	proportions	of	third-generation	cephalosporin-
resistant	 E. coli	 and	 of	 MRSA	 were	 recorded	 for	 each	
year	from	2002	to	2009.	To	assess	the	patterns	of	com-
bined	 resistance	of	E. coli,	 the	 following	antimicrobial	
classes	were	analysed:	aminopenicillins	(ampicillin	and	
amoxicillin),	 aminoglycosides	 (gentamicin,	 tobramy-
cin	 and	 amikacin),	 third-generation	 cephalosporins	
(ceftriaxone,	 cefotaxime	 and	 ceftazidime)	 and	 fluoro-










of	 E. coli	 and	 S. aureus	 isolates	 reported	 yearly	 per	
country	ranged	from	96	to	1,973	and	from	56	to	1,290,	
respectively	(Table).	
Considering	 the	 whole	 group	 of	 selected	 laborato-
ries,	 the	 reported	number	of	E. coli	BSIs	 increased	by	
71%	from	10,688	in	2002	to	18,240	in	2009	(Figure	1);	
most	of	 the	 rise	 (38%	of	 71%)	 in	E. coli	 BSIs	was	due	
to	 isolates	 resistant	 to	 two	 or	 more	 antimicrobials.	
During	the	same	period,	S. aureus	BSIs	showed	a	34%	
increase	 from	7,855	 to	 10,503	 (Figure	 1).	 In	 the	period	
from	 2002	 to	 2009,	 if	 only	 E.coli	 susceptible	 to	 ami-







losporins	 increased	 significantly	 from	 1.7%	 to	 8%	
(p<0.001)	and	the	proportion	of	MRSA	decreased	from	
21.5%	 to	 19.7%	 (p<0.001)	 (Figure	 2).	 Similar	 trends	 of	





Mean annual number of Escherichia coli and Staphylococcus aureus isolates per country reported by laboratories (n=198) 
reporting continuously to EARSS/EARS-Net, 2002–09
Country Number of laboratories
Number of Escherichia coli isolates Number of Staphylococcus aureus isolates
Mean per year (2002–09) Mean per year (2002–09)
Austria 10 802 630
Belgium 9 646 343
Bulgaria 7 96 82
Czech Republic 33 1,837 1,290
Estonia 5 142 125
Finland 5 849 381
France 12 1,583 1,018
Germany 2 156 121
Greece 22 829 472
Hungary 14 446 526
Iceland 1 97 56
Ireland 15 1,086 961
Italy 3 237 166
Luxembourg 4 176 80
Malta 1 104 96
Netherlands 4 291 238
Norway 7 975 467
Portugal 8 559 574
Slovenia 9 572 321
Spain 19 1,973 835
Sweden 3 578 331
United Kingdom 5 641 373
EARSS:	European	Antimicrobial	Resistance	Surveillance	System;	EARS-Net:	European	Antimicrobial	Resistance	Surveillance	Network.
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Combined	 resistance	 in	 E. coli	 (defined	 as	 resistance	
to	 two,	 three	 or	 four	 antimicrobial	 classes	 reported	
to	 EARS-Net)	 showed	 a	 significant	 increase	 (p<0.001)	






The	 increase	 in	 antimicrobial	 resistance	 in	 E. coli	
between	 2002	 and	 2009	 was	 evident	 both	 in	 the	
observed	 increase	 of	 combined	 resistance	 and	 in	 the	
reduction	 of	 full	 susceptibility	 to	 the	 antimicrobi-
als	 included	 in	 the	 analysis.	 In	 the	 same	 time	 period	
and	 considering	 the	 same	 data	 source,	 a	 significant	
decrease	of	meticillin	resistance	was	observed	for
S. aureus.	 For	 this	 species,	 the	 number	 of	 BSIs	
increased	 less	 (+34%)	 than	 for	 E. coli	 BSI	 (+71%).	
Consistently,	 increasing	 resistance	 in	E. coli	 and	com-
bined	resistance	of	 invasive	and	non-invasive	 isolates	





by	 56%	 between	 2004	 and	 2008	 [9],	 and	 in	 France	 a	
significant	 decrease	 in	 the	 occurrence	 of	 MRSA	 was	
reported	 in	 2008	 [10].	 A	 similar	 reduction	 in	 the	 rate	
of	 healthcare-associated	 invasive	 MRSA	 infections	




ation	 in	 the	 size	 of	 the	 catchment	 population	 behind	
the	numbers.	Based	on	the	available	surveillance	data,	
it	 provides	 the	 best	 possible	 evidence	 of	 the	 increas-
ing	burden	of	disease	caused	by	E. coli	 and	S. aureus	
bacteraemia	 in	 the	 European	 Union.	 Nevertheless,	 if	
the	 population	 covered	 by	 the	 participating	 laborato-
ries	 became	 larger	 during	 the	 study	 period,	 this	may	
have	 contributed	 to	 the	 observed	 increase.	 Likewise,	
the	 sample	 approach	 includes	 laboratories	 without	





be	 caused	 by	 an	 increase	 of	 empirical	 treatment	 fail-
ures	 triggering	 delayed	 diagnostic	 procedures	 (blood	
culture).	 A	 similar	 upward	 trend	 in	 the	 number	 of	
reported	 cases	 of	 E. coli	 BSIs	 has	 been	 observed	 by	
Figure 2
Proportion of third-generation cephalosporin-resistant 
Escherichia coli and of meticillin-resistant Staphylococcus 




























Thi rd-generation cephalosporin-resistant E. col i  among total  E. col i
MRSA among total  S. aureus
Figure 1
Annual number of bloodstream infections caused by 
Escherichia coli and Staphylococcus aureus, EARSS/EARS-





























E. coli S. aureus
Figure 3
Combined resistance of Escherichia coli to 
aminopenicillins, third-generation cephalosporins, 
fluoroquinolones and aminoglycosides, EARSS/EARS-Net, 
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Despite	 the	 study	 limitations,	 the	 observed	 trends	
regarding	 resistance	 to	 third-generation	 cepha-
losporins	 and	 combined	 resistance	 in	 E. coli	 deserve	
further	 consideration.	 According	 to	 the	 results,	 it	
appears	 that	 the	 emergence	 and	 spread	 of	 combined	
resistance	during	the	study	period	was	the	main	factor	

















Resistance	 trends	 were	 monitored	 using	 interpreta-
tions:	 susceptible,	 intermediate	 or	 resistant	 (SIR)	 [3],	
since	 the	 actual	 minimum	 inhibitory	 concentrations	
(MIC)	 were	 not	 systematically	 available	 from	 partici-
pating	 laboratories.	 Reporting	 MICs	 rather	 than	 SIR	
interpretations	 based	 on	 clinical	 breakpoints	 would	
improve	the	dynamic	monitoring	of	subtle,	incremental	
changes	 in	 antimicrobial	 susceptibility.	Moreover,	 the	
interpretation	 using	 SIR	 categories	 reported	 to	 EARS-
Net	 is	based	on	breakpoints	defined	 in	 the	participat-
ing	 countries’	 guidelines	 over	 time.	 Nevertheless,	 for	
the	 combinations	 of	microorganisms	 and	 antimicrobi-






not	 contained,	 the	 use	 of	 carbapenems	 will	 increase	
favouring	 the	 emergence	 of	 carbapenemase	 produc-
ing	enterobacteria.	This	has	been	already	observed	for	






be	 the	 result	 of	 public	 health	 efforts	 targeted	 at	 the	
containment	 of	MRSA	 in	 several	 European	 countries.*	
Although	an	overall	decreasing	 trend	 for	MRSA	 is	evi-
dent	 in	 Europe,	 not	 all	 countries	 contribute	 to	 this	
result.	Efforts	to	reduce	the	occurrence	of	MRSA	should	
remain	a	priority	irrespective	of	decreasing	trends.	
In	 this	 context,	 coordinated	 international	 surveillance	




At	 the	 request	 of	 the	 authors,	 the	 following	 correction	 was	made	
on	 18	March	 2011:	 The	 sentence	 ‘This	 could	 be	 the	 result	 of	 pub-
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D’Ancona,	 S	 Iannazzo,	 A	 Pantosti;	 Latvia:	 R	 Nikiforova;	 Lithuania:	
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